France-based Doctolib, a booking service for doctors and medical workers, raises €500M in equity and debt led by Eurazeo at a €5.8B valuation
Romain Dillet / TechCrunch :
Context & Ripple Effects
Doctolib's €500M raise caps a steady climb: an early $42M round in 2017, then a $170M Series C at a $1.1B valuation in 2019 — today's €5.8B marks roughly a fivefold jump in three years, with Eurazeo now leading after backing French SaaS peer PayFit's Series D last year.
First-order effects
- Doctolib gains a war chest sized for European expansion and product build-out beyond appointment booking, while Eurazeo adds a flagship health-tech position to its portfolio alongside PayFit.
Second-order effects
- Rival DocPlanner, which raised a €80M Series E in 2019, faces a competitor with several times its disclosed funding — forcing either accelerated fundraising or retreat from head-to-head markets.
- The round puts Doctolib near the scale of China's WeDoctor, which raised $500M at a $5.5B valuation in 2018, signaling that Europe can now produce homegrown booking platforms at global-health-platform size rather than ceding the category.
Third-order effects
- If the pattern holds, European digital health consolidates around a few heavily capitalized national champions — with France emerging as the anchor market, as seen in adjacent players like hospital-messaging startup Lifen — and late-stage capital increasingly flows through repeat lead investors like Eurazeo rather than scattered seed syndicates.
The trend: European healthcare booking is consolidating into a handful of mega-funded national platforms, with Doctolib's valuation leap marking the shift from regional startup to continental incumbent.